Search

Your search keyword '"Sanpaolo, Grazia"' showing total 47 results
Start Over Author "Sanpaolo, Grazia" Language english
47 results on '"Sanpaolo, Grazia"'

1. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)

Author

Mele, Anna, Prete, Eleonora, De Risi, Clara, Citiso, Stefania, Greco, Giuseppina, Falcone, Antonietta Pia, Sanpaolo, Grazia, Mele, Giuseppe, Giannotta, Angela, Vergine, Carolina, Reddiconto, Giovanni, Palazzo, Giulia, Sabatelli, Sabrina, Germano, Candida, Miccolis, Rosanna, Curci, Paola, Palumbo, Gaetano, Offidani, Massimo, Rizzi, Rita, Cascavilla, Nicola, Pastore, Domenico, Di Renzo, Nicola, Mazza, Patrizio, Tarantini, Giuseppe, Guarini, Attilio, Capalbo, Silvana, Specchia, Giorgina, Greco, Antonino, De Francesco, Rosa, Sibilla, Silvia, Tonialini, Lorenzo, Morciano, Maria Rosaria, and Pavone, Vincenzo

Published
2021
Full Text
View/download PDF

2. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Author

Oliva, Esther N, Alati, Caterina, Santini, Valeria, Poloni, Antonella, Molteni, Alfredo, Niscola, Pasquale, Salvi, Flavia, Sanpaolo, Grazia, Balleari, Enrico, Germing, Ulrich, Fenaux, Pierre, Stamatoullas, Aspasia, Palumbo, Giuseppe A, Salutari, Prassede, Impera, Stefana, Avanzini, Paolo, Cortelezzi, Agostino, Liberati, Anna Marina, Carluccio, Paola, Buccisano, Francesco, Voso, Maria Teresa, Mancini, Stefano, Kulasekararaj, Austin, Morabito, Fortunato, Bocchia, Monica, Cufari, Patrizia, Spiriti, Maria Antonietta Aloe, Santacaterina, Irene, D'Errigo, Maria Grazia, Bova, Irene, Zini, Gina, and Latagliata, Roberto

Published
2017
Full Text
View/download PDF

3. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

Author

Efficace, Fabio, Gaidano, Gianluca, Breccia, Massimo, Voso, Maria Teresa, Cottone, Francesco, Angelucci, Emanuele, Caocci, Giovanni, Stauder, Reinhard, Selleslag, Dominik, Sprangers, Mirjam, Platzbecker, Uwe, Ricco, Alessandra, Sanpaolo, Grazia, Beyne-Rauzy, Odile, Buccisano, Francesco, Palumbo, Giuseppe A, Bowen, David, Nguyen, Khanh, Niscola, Pasquale, Vignetti, Marco, and Mandelli, Franco

Published
2015
Full Text
View/download PDF

4. PB2670: EQOL‐MDS TRIAL: PATIENT‐REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.

Author

Oliva, Esther, Iannì, Giuseppe, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Gaidano, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Sanpaolo, Grazia, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Castelli, Andrea, Fattizzo, Bruno, and Beltrami, Germana

Published
2023
Full Text
View/download PDF

6. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

Author

Efficace, Fabio, Santini, Valeria, La Nasa, Giorgio, Cottone, Francesco, Finelli, Carlo, Borin, Lorenza, Quaresmini, Giulia, Di Tucci, Anna Angela, Volpe, Antonio, Cilloni, Daniela, Quarta, Giovanni, Sanpaolo, Grazia, Rivellini, Flavia, Salvi, Flavia, Molteni, Alfredo, Voso, Maria Teresa, Alimena, Giuliana, Fenu, Susanna, Mandelli, Franco, and Angelucci, Emanuele

Published
2016
Full Text
View/download PDF

7. Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes

Author

Musto, Pellegrino, Villani, Oreste, Martorelli, Maria Carmen, Pietrantuono, Giuseppe, Guariglia, Roberto, Mansueto, Giovanna, D’Auria, Fiorella, Grieco, Vitina, Bianchino, Gabriella, Sparano, Anna, Zonno, Antonia, Lerose, Rosa, Sanpaolo, Grazia, and Falcone, Antonietta

Published
2010
Full Text
View/download PDF

8. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes

Author

Efficace, Fabio, Gaidano, Gianluca, Breccia, Massimo, Criscuolo, Marianna, Cottone, Francesco, Caocci, Giovanni, Bowen, David, Lübbert, Michael, Angelucci, Emanuele, Stauder, Reinhard, Selleslag, Dominik, Platzbecker, Uwe, Sanpaolo, Grazia, Jonasova, Anna, Buccisano, Francesco, Specchia, Giorgina, Palumbo, Giuseppe A., Niscola, Pasquale, Wan, Chonghua, Zhang, Huiyong, Fenu, Susanna, Klimek, Virginia, Beyne-Rauzy, Odile, Nguyen, Khanh, and Mandelli, Franco

Published
2015
Full Text
View/download PDF

9. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study

Author

Oliva, Esther Natalie, Cuzzola, Maria, Aloe Spiriti, Maria Antonietta, Poloni, Antonella, Laganà, Carmelo, Rigolino, Carmela, Morabito, Fortunato, Galimberti, Sara, Ghio, Riccardo, Cortelezzi, Agostino, Palumbo, Giuseppe Alberto, Sanpaolo, Grazia, Finelli, Carlo, Ricco, Alessandra, Volpe, Antonio, Rodà, Filippo, Breccia, Massimo, Alimena, Giuliana, Nobile, Francesco, and Latagliata, Roberto

Published
2013
Full Text
View/download PDF

10. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)

Author

Angelucci, Emanuele, Santini, Valeria, Di Tucci, Anna Angela, Quaresmini, Giulia, Finelli, Carlo, Volpe, Antonio, Quarta, Giovanni, Rivellini, Flavia, Sanpaolo, Grazia, Cilloni, Daniela, Salvi, Flavia, Caocci, Giovanni, Molteni, Alfredo, Vallisa, Daniele, Voso, Maria Teresa, Fenu, Susanna, Borin, Lorenza, Latte, Giancarlo, Alimena, Giuliana, Storti, Sergio, Piciocchi, Alfonso, Fazi, Paola, Vignetti, Marco, and Tura, Sante

Published
2014
Full Text
View/download PDF

11. Advanced mast cell disease: an Italian Hematological Multicenter experience

Author

Pagano, Livio, Valentini, Caterina Giovanna, Caira, Morena, Rondoni, Michela, Van Lint, Maria Teresa, Candoni, Anna, Allione, Bernardino, Cattaneo, Chiara, Marbello, Laura, Caramatti, Cecilia, Pogliani, Enrico Maria, Iannitto, Emilio, Giona, Fiorina, Ferrara, Felicetto, Invernizzi, Rosangela, Fanci, Rosa, Lunghi, Monia, Fianchi, Luana, Sanpaolo, Grazia, Stefani, Pietro Maria, Pulsoni, Alessandro, Martinelli, Giovanni, Leone, Giuseppe, and Musto, Pellegrino

Published
2008
Full Text
View/download PDF

12. Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: Case-control study in patients with multiple myeloma and review of the literature

Author

Musto, Pellegrino, Scalzulli, Potito Rosario, Terruzzi, Elisabetta, Rossini, Fausto, Iacopino, Pasquale, Messina, Giuseppe, Guariglia, Roberto, Pietrantuono, Giuseppe, Villani, Oreste, D’Auria, Fiorella, Falcone, Antonietta, Sanpaolo, Grazia, Valvano, Maria Rosa, Pogliani, Enrico Maria, and Morabito, Fortunato

Published
2007
Full Text
View/download PDF

13. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide

Author

Musto, Pellegrino, Falcone, Antonietta, Sanpaolo, Grazia, Guglielmelli, Tommasina, Zambello, Renato, Balleari, Enrico, Catalano, Lucio, Spriano, Mauro, Cavallo, Federica, Sala, Antonio La, Mantuano, Saverio, Nobile, Michele, Melillo, Lorella, Scalzulli, Potito Rosario, Dell’Olio, Matteo, Bodenizza, Carlo, Greco, Michele Mario, Carella, Angelo Michele, Jr., Merla, Emanuela, Carella, Angelo Michele, Boccadoro, Mario, Cascavilla, Nicola, and Palumbo, Antonio

Published
2006
Full Text
View/download PDF

19. Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study

Author

Gugliotta, Gabriele, Annunziata, Mario, Capodanno, Isabella, Rapezzi, Davide, Attolico, Immacolata, Vincelli, Iolanda Donatella, Tiribelli, Mario, Malato, Alessandra, Pizzuti, Michele, Accurso, Vincenzo, Bonifacio, Massimiliano, Galimberti, Sara, Loglisci, Giuseppina, Abruzzese, Elisabetta, Bocchia, Monica, Gozzini, Antonella, Bergamaschi, Micaela, Miggiano, Maria Cristina, Tafuri, Agostino, Sanpaolo, Grazia, Binotto, Gianni, Castagnetti, Fausto, Specchia, Giorgina, Di Raimondo, Francesco, Cavo, Michele, Rosti, Gianantonio, Foà, Robin, Saglio, Giuseppe, Breccia, Massimo, and Stagno, Fabio

Published
2020
Full Text
View/download PDF

20. Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial

Author

Oliva, Esther Natalie, Alati, Caterina, Santini, Valeria, Poloni, Antonella, Riva, Marta, Niscola, Pasquale, Giai, Valentina, Sanpaolo, Grazia, Balleari, Enrico, Crisà, Elena, Ferrero, Dario, Germing, Ulrich, Fenaux, Pierre, Palumbo, Giuseppe A., Salutari, Prassede, Impera, Stefana, Capodanno, Isabella, Reda, Gianluigi, Liberati, Anna Marina, Molteni, Alfredo, Specchia, Giorgina, Buccisano, Francesco, Voso, Maria Teresa, Mancini, Stefano, Bocchia, Monica, Candoni, Anna, Martino, Bruno, Cufari, Patrizia, D'Errigo, Maria Grazia, Zini, Gina, and Latagliata, Roberto

Published
2019
Full Text
View/download PDF

21. P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL.

Author

Breccia, Massimo, Iurlo, Alessandra, Ferrara, Felicetto, Attolico, Immacolata, Malato, Alessandra, Bonifacio, Massimiliano, Rita Scortechini, Anna, Abruzzese, Elisabetta, Sanpaolo, Grazia, DI Renzo, Nicola, Lunghi, Monia, Impera, Stefana, Castagnetti, Fausto, Tiribelli, Mario, Santoro, Marco, Lunghi, Francesca, Maggi, Alessandro, Sargentini, Valeria, Piciocchi, Alfonso, and Tringali, Claudia

Published
2023
Full Text
View/download PDF

22. Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients

Author

Efficace, Fabio, Niscola, Pasquale, Patriarca, Andrea, Cottone, Francesco, Palumbo, Giuseppe A., Caocci, Giovanni, Fedele, Marilena, Platzbecker, Uwe, Stauder, Reinhard, Petranovic, Duska, Ricco, Alessandra, Breccia, Massimo, Frairia, Chiara, Luppi, Mario, Invernizzi, Rosangela, Sanpaolo, Grazia, Crugnola, Monica, Fianchi, Luana, Vallisa, Daniele, Voso, Maria Teresa, Fozza, Claudio, Santini, Valeria, Caers, Jo, Capodanno, Isabella, Sarlo, Chiara, Pelaez Doro, Maribel, Bergamaschi, Micaela, Zhang, Huiyong, Lubbert, Michael, Canicattì, Manuela, Kyriakou, Charalampia, Di Renzo, Nicola, Cuneo, Antonio, Karakantza, Marina, and Vignetti, Marco

Published
2018
Full Text
View/download PDF

23. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program

Author

Musto, Pellegrino, Maurillo, Luca, Spagnoli, Alessandra, Gozzini, Antonella, Rivellini, Flavia, Lunghi, Monia, Villani, Oreste, Aloe Spiriti, Maria Antonietta, Venditti, Adriano, Santini, Valeria, Leone, Giuseppe, Voso, Maria Teresa, D'Arco, Alfonso Maria, Tatarelli, Caterina, Ferrero, Dario, Gaidano, Gianluca, Palumbo, Giuseppe, Di Raimondo, Francesco, Oliva, Esther, Sanpaolo, Grazia, Tonso, Anna, Santagostino, Alberto, Filardi, Nunzio, Pollio, Berardino, Candoni, Anna, Fili, Carla, Russo, Domenico, Orciuolo, Enrico, Petrini, Mario, Ciuffreda, Lucia, Riezzo, Antonio, Morabito, Fortunato, Mazza, Patrizio, Pastore, Domenico, Specchia, Giorgina, and Ferrara, Felicetto

Subjects
Azacitidine, Hypomethylating agents, International prognostic, Myelodysplastic syndromes, Prognosis, Scoring system, Transfusion, Adult, Aged, Aged, 80 and over, Antimetabolites, Antineoplastic, Drug Evaluation, Female, Humans, Italy, Male, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Risk, Treatment Outcome, Cancer Research, Oncology, Antimetabolites, 80 and over, hypomethylating agents, Antineoplastic, myelodysplastic syndromes, International Prognostic Scoring System, medicine.drug, medicine.medical_specialty, azacitidine, medicine.drug_class, Lower risk, Antimetabolite, Internal medicine, azacitidine,hypomethylating agents,myelodysplastic syndromes,prognosis,International Prognostic Scoring System,transfusion, medicine, Risk factor, Adverse effect, transfusion, business.industry, Retrospective cohort study, medicine.disease, Surgery, prognosis, business, Settore MED/15 - Malattie del Sangue
Abstract

BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high-risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have lower risk MDS. METHODS: The authors retrospectively evaluated 74 patients with International Prognostic Scoring System low-risk or intermediate 1-risk MDS, who received azacitidine on a national named patient program. At baseline, 84% of patients were transfusion-dependent, 57% had received erythropoietin, and 51% were aged > 70 years. Azacitidine was administered subcutaneously for 5 days (n ¼ 29 patients), 7 days (n ¼ 43 patients), or 10 days (n ¼ 2 patients) every month at a dose of 75 mg/m2 daily (n ¼ 45 patients) or at a fixed dose of 100 mg daily (n ¼ 29 patients) and for a median of 7 cycles (range, 1-30 cycles). RESULTS: According to the 2006 International Working Group criteria, overall response rate (ORR) was 45.9%, including complete responses (10.8%), partial responses (9.5%), hematologic improvements (20.3%), and bone marrow complete responses (5.4%).The ORR was 51.6% in 64 patients who completed at least 4 cycles of treatment. The median duration of response was 6 months (range, 1-30 months). After a median follow-up of 15 months, 71% of patients remained alive. A survival benefit was observed in responders versus nonresponders (94% vs 54% of patients projected to be alive at 2.5 years, respectively; P < .0014). The most common grade 3 or 4 adverse events were myelosuppression (21.6%) and infection (6.8%). CONCLUSIONS: The current results indicated that azacitidine may be a feasible and effective treatment for patients with lower risk MDS.

Published
2010

24. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.

Author

Oliva, Esther N., Lauseker, Michael, Aloe Spiriti, Maria Antonietta, Poloni, Antonella, Cortelezzi, Agostino, Palumbo, Giuseppe A., Balleari, Enrico, Sanpaolo, Grazia, Volpe, Antonio, Ricco, Alessandra, Ronco, Francesca, Alati, Caterina, D'Errigo, Maria Grazia, Santacaterina, Irene, Kündgen, Andrea, Germing, Ulrich, and Latagliata, Roberto

Subjects
MYELODYSPLASTIC syndromes treatment, THALIDOMIDE, BLOOD transfusion, ANEMIA, QUALITY of life, THERAPEUTICS
Abstract

Lenalidomide is approved for the treatment of transfusion-dependent (TD) del(5q) myelodysplastic syndromes (MDS). However, few data are available in patients with transfusion-independent (TI) del(5q) MDS. In the first, observational, part of this 2-part study, we assessed the impact of transfusion dependence on overall survival (OS) and non-leukemic death in untreated del(5q) MDS patients who were TD (n = 136), TI with hemoglobin (Hb) ≥10 mg/dL (n = 88), or TI with Hb <10 mg/dL (n = 96). In the second, interventional, part we assessed the quality-of- life (QoL) benefits and clinical efficacy of lenalidomide (10 mg/day) in 12 patients with TI del(5q) MDS and Hb <10 mg/ dL. In the untreated population, OS was significantly longer in TI than in TD patients (TI [Hb ≥10 g/dL], 108 months; TI [Hb <10 g/dL], 77 months; TD, 44 months). Transfusion dependence also negatively impacted non-leukemic death rates. In the interventional part of the study, baseline Hb levels were found to correlate significantly with physical (R = 0.666, P = 0.035) and fatigue (R = 0.604, P = 0.049) QoL scores. Median physical QoL scores improved significantly after 12 weeks’ treatment with lenalidomide (+12.5; P = 0.020). Evaluable TI patients experienced early increases in Hb levels, and all attained an erythroid response. Our findings suggest that TI patients with moderate anemia may benefit from early treatment with lenalidomide. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

25. Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial

Author

Oliva, Esther Natalie, Santini, Valeria, Alati, Caterina, Poloni, Antonella, Molteni, Alfredo, Niscola, Pasquale, Sanpaolo, Grazia, Salvi, Flavia, Palumbo, Giuseppe A., Balleari, Enrico, Impera, Stefana, Cortelezzi, Agostino, Liberati, Anna Marina, Avanzini, Paolo, Di Bartolomeo, Paolo, Rose, Christian, Beyne-Rauzy, Odile, Buccisano, Francesco, Bocchia, Monica, Morabito, Fortunato, Stamatoullas, Aspasia, Ronco, Francesca, Zini, Gina, D'Errigo, Maria Grazia, Ranieri, Natale, Cufari, Patrizia, Santacaterina, Irene, Fenaux, Pierre, and Latagliata, Roberto

Published
2015
Full Text
View/download PDF

26. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.

Author

Oliva, Esther N., Latagliata, Roberto, Laganà, Carmelo, Breccia, Massimo, Galimberti, Sara, Morabito, Fortunato, Poloni, Antonella, Balleari, Enrico, Cortelezzi, Agostino, Palumbo, Giuseppe, Sanpaolo, Grazia, Volpe, Antonio, Specchia, Giorgina, Finelli, Carlo, D'Errigo, Maria Grazia, Rodà, Filippo, Alati, Caterina, Alimena, Giuliana, Nobile, Francesco, and Aloe Spiriti, Maria A.

Subjects
HEALTH outcome assessment, DRUG efficacy, MYELODYSPLASTIC syndromes, QUALITY of life, THALIDOMIDE, PATIENTS
Abstract

In lower-risk myelodysplastic syndromes (MDS) with del(5q), lenalidomide induces erythroid responses associated with better survival. In a phase II, single-arm trial, 45 patients with anemia and lower-risk del(5q) MDS received lenalidomide 10 mg/day to evaluate quality of life (QoL) changes, measured by QOL-E, safety, responses and survival. Lenalidomide was well tolerated, with 80% completing ≥ 24 weeks of treatment. Earlier study discontinuation was related to disease progression ( n = 5), death ( n = 1) and withdrawal of consent ( n = 3). Within 24 weeks, 82% obtained erythroid responses, durable in 69% at 52 weeks. Cytogenetic responses occurred in 29 patients (64%), with 10 patients achieving a complete cytogenetic response. QoL-E scores correlated with hemoglobin levels and improved in erythroid responders. Erythroid responders had an 86% reduced risk of disease progression and an 80% reduction in mortality risk compared with non-responders. These findings corroborate earlier studies and give further support to the use of lenalidomide in lower-risk MDS and del(5q). [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

27. Health-Related Quality Of Life In Transfusion-Dependent Patients With Myelodysplastic Syndromes Treated With Deferasirox. A Multicenter Prospective Study

Author

Efficace, Fabio, Santini, Valeria, La Nasa, Giorgio, Cottone, Francesco, Finelli, Carlo, Borin, Lorenza, Quaresmini, Giulia, Di Tucci, Anna, Volpe, Antonio, Cilloni, Daniela, Quarta, Giovanni, Sanpaolo, Grazia, Rivellini, Flavia, Salvi, Flavia, Molteni, Alfredo, Vallisa, Daniele, Storti, Sergio, Voso, Maria Teresa, Alimena, Giuliana, Fenu, Susanna, Vignetti, Marco, Mandelli, Franco, and Angelucci, Emanuele

Published
2013
Full Text
View/download PDF

28. Efficacy and Safety of Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Analysis of a Prospective, Randomized, Single-Blind, Placebo-Controlled Trial (EQoL-MDS)

Author

Oliva, Esther Natalie, Santini, Valeria, Zini, Gina, Palumbo, Giuseppe A, Poloni, Antonella, Cortelezzi, Agostino, Voso, Maria Teresa, Molteni, Alfredo, Sanpaolo, Grazia, Marino, Antonio, Rodà, Filippo, Alati, Caterina, Ronco, Francesca, Raimondo, Francesco Di, Leoni, Pietro, Alimena, Giuliana, Finotto, Silvia, Latagliata, Roberto, and Nobile, Francesco

Published
2012
Full Text
View/download PDF

29. Non-pegylated liposomal doxorubicin (Myocet®®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma.

Author

Dell'olio, Matteo, Potito scalzulli, Rosario, Sanpaolo, Grazia, Nobile, Michele, Saverio mantuano, Francesco, La sala, Antonio, D'arena, Giovanni, Miraglia, Eustachio, Lucania, Anna, Mastrullo, Lucia, and Nicola, Cascavilla

Subjects
B cell lymphoma, DOXORUBICIN, NEUTROPENIA, CYCLOPHOSPHAMIDE, DISEASE incidence, PATIENTS
Abstract

The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet®® 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg/m2, prednisone 100 mg/day). In all, 82.5%% and 13.7%% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%%), while 3/80 are alive with active disease and 15 patients (18.7%%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6 ±± 6.9%% to 54.2 ±± 3.9%%). Grade 3--4 neutropenia occurred in 22%% of patients. We concluded that Myocet®® shows both efficacy and tolerability, mainly at the cardiac level. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

30. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

Author

D'arena, Giovanni, Gobbi, Paolo G., Broglia, Chiara, Sacchi, Stefano, Quarta, Giovanni, Baldini, Luca, Iannitto, Emilio, Falcone, Antonietta, Guariglia, Roberto, Pietrantuono, Giuseppe, Villani, Oreste, Martorelli, Maria Carmen, Mansueto, Giovanna, Sanpaolo, Grazia, Cascavilla, Nicola, and Musto, Pellegrino

Subjects
CLINICAL trials, MULTIPLE myeloma treatment, DISODIUM pamidronate, DRUG administration, DISEASE progression
Abstract

A prospective, multicenter, randomized trial comparing pamidronate administration (60--90 mg once a month for 1 year) versus simple observation in 177 patients with asymptomatic myeloma was performed to explore whether the administration of this drug reduces the rate of and/or the time to progression to overt, symptomatic disease. No relevant side effects were recorded in pamidronate-treated patients. With a minimum follow-up of 5 years for live patients, there were 56/89 (62.9%%) progressions in the pamidronate-treated group and 55/88 (62.5%%) within the controls ( p == NS). Median time to progression was 46 and 48 months, respectively ( p == NS). Overall survival was also similar between the two groups. Skeletal-related events at the time of progression were observed in 40/55 (72.7%%) controls, but only in 22/56 (39.2%%) pamidronate-treated patients ( p == 0.009). In conclusion, the administration of pamidronate in asymptomatic myeloma, while reducing bone involvement at progression, did not decrease the risk of transformation and the time to progression into overt myeloma. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

31. Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis.

Author

Musto, Pellegrino, Falcone, Antonietta, Sanpaolo, Grazia, Bodenizza, Carlo, Perla, Gianni, Minervini, Maria Marta, Cascavilla, Nicola, Dell'Olio, Matteo, La Sala, Antonio, Mantuano, Saverio, Melillo, Lorella, Nobile, Michele, Scalzulli, Potito Rosario, Bisceglia, Michele, and Carella, Angelo Michele

Subjects
METHANESULFONATES, TYROSINE, CYTOLOGY, GENETICS, CELL proliferation, SYNDROMES
Abstract

Four cases of hypereosinophilic syndrome (HES) treated with the tyrosine-kinase inhibitor imatinibmesylate are reported. The drug was effective in three patients, but a prolonged clinical and hematological remission was obtained only in one patient, due to appearance of resistance or poor tolerability in the other cases. The dose of imatinib necessary to achieve a response ranged from 100 to 600 mg/d. One patient with evidence of a clonal T-cell population did not respond at all. We confirm the efficacy of imatinib in HES, but we also underline that type and duration of response may be variable. This could be due to different pathogenetic mechanisms of the disease in single patients. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

32. Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial.

Author

Musto, Pellegrino, Falcone, Antonietta, Sanpaolo, Grazia, Bodenizza, Carlo, Cascavilla, Nicola, Melillo, Lorella, Rosario Scalzulli, Potito, Dell'Olio, Matteo, La Sala, Antonio, Mantuano, Saverio, Nobile, Michele, and Michele Carella, Angelo

Subjects
PATIENTS, INFUSION therapy, THERAPEUTICS, DRUG therapy, RADIOTHERAPY
Abstract

Ninety patients with untreated, stage I-II A myeloma, were randomised to receive or not monthly infusions of pamidronate (PMD) for 1 year, without additional therapies. Follow-up ranged from 36 to 72 months (median 51 months). Three years after the start of the treatment, the disease had progressed in 25% of PMD treated patients and in 26.8% of controls (p n.s). Median time-to-progression was 16 and 17.4 months, respectively (p n.s). Among the 21 patients who required chemo-radiotherapy, skeletal events (osteolytic lesions, pathological fractures and/or hypercalcemia) developed in 9/11 (81.8%) controls and in 4/10 (40%) of treated patients (p < 0.01). "Prophylactic" administration of PMD may decrease the development of skeletal events, but does not reduce the rate and the time of disease progression in early-stage myeloma. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

33. Safety and Efficacy of Laparoscopic Splenectomy in Patients with Refractory Immune Thrombocytopenic Purpura. A Long-Term Survey

Author

Cascavilla, Nicola, Scaramuzzi, Matteo, Nobile, Michele, Dell'Olio, Matteo, Falcone, Antonietta Pia, Melillo, Lorella, Sanpaolo, Grazia, Scalzulli, Potito Rosario, Rossi, Giovanni, La Sala, Antonio, Bodenizza, Carlo, D'Arena, Giovanni, Mantuano, Francesco Saverio, Greco, Michele Mario, Carella, Angelo Michele, Merla, Emanuela, Ambrosio, Angelo, and Di Sebastiano, Pierluigi

Published
2008
Full Text
View/download PDF

34. 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program

Author

Musto, Pellegrino, Maurillo, Luca, Spagnoli, Alessandra, Gozzini, Antonella, Rivellini, Flavia, Tatarelli, Caterina, Lunghi, Monia, Fili, Carla, Orciuolo, Enrico, Ciuffreda, Lucia, Vigna, Ernesto, Cioppa, Paola Della, Candoni, Anna, Ferrero, Dario, Palmieri, Salvatore, Palumbo, Giuseppe, Di Renzo, Nicola, Oliva, Esther, Sanpaolo, Grazia, Pastore, Domenico, Tonso, Anna, Santagostino, Alberto, Rocco, Stefano, Villani, Oreste, D'Auria, Fiorella, D'Arco, Alfonso Maria, Gaidano, Gianluca, Galimberti, Sara, Russo, Domenico, Venditti, Adriano, Aloe-Spiriti, Maria Antonietta, Leone, Giuseppe, and Santini, Valeria

Published
2008
Full Text
View/download PDF

35. 5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.

Author

Maurillo, Luca, Spagnoli, Alessandra, Genuardi, Mariella, Lunghi, Monia, Di Renzo, Nicola, D'Arco, Alfonso Maria, Mele, Giuseppe, Levis, Alessandro, Gozzini, Antonella, Petrini, Mario, Mianulli, Manuela, Sanpaolo, Grazia, Santagostino, Alberto, Pietrantuono, Giuseppe, D'Auria, Fiorella, Ferrero, Dario, Gaidano, Gianluca, Ferrara, Felicetto, Venditti, Adriano, Leone, Giuseppe, Santini, Valeria, and Musto, Pellegrino

Published
2008
Full Text
View/download PDF

37. Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma.

Author

Musto, Pellegrino, Petrucci, Maria Teresa, Bringhen, Sara, Guglielmelli, Tommasina, Caravita, Tommaso, Balleari, Enrico, Andriani, Alessandro, D'Arena, Giovanni, Bongarzoni, Velia, Guariglia, Roberto, Pietrantuono, Giuseppe, Villani, Oreste, Martorelli, Maria Carmen, D'Auria, Fiorella, Niscola, Pasquale, Falcone, Antonietta, Sanpaolo, Grazia, and Palumbo, Antonio

Published
2007
Full Text
View/download PDF

40. Systemic Mastocytosis. A GIMEMA Multicenter Survey.

Author

Pagano, Livio, Valentini, Caterina Giovanna, Musto, Pellegrino, Caira, Morena, Rondoni, Michela, Van Lint, Maria Teresa, Candoni, Anna, Martinelli, Giovanni, Gatto, Simona, Cattaneo, Chiara, Marbello, Laura, Caramatti, Cecilia, Castagnola, Carlo, Pogliani, Enrico Maria, Mitra, Maria Enza, Giona, Fiorina, Fanci, Rossella, Fianchi, Luana, Sanpaolo, Grazia, Pulsoni, Alessandro, and Leone, Giuseppe

Published
2006
Full Text
View/download PDF

43. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Author

Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, and Della Porta MG

Subjects
Humans, Activin Receptors, Type II, Immunoglobulin Fc Fragments, Myelodysplastic Syndromes drug therapy, Anemia, Sideroblastic drug therapy
Published
2023
Full Text
View/download PDF

44. Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.

Author

Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, Tiribelli M, Stagno F, Caocci G, Martino B, Luciano L, Pizzuti M, Gozzini A, Scortechini AR, Albano F, Bergamaschi M, Capodanno I, Patriarca A, Fava C, Rege-Cambrin G, Sorà F, Galimberti S, Bocchia M, Binotto G, Reddiconto G, DiTonno P, Maggi A, Sanpaolo G, De Candia MS, Giai V, Abruzzese E, Miggiano MC, La Barba G, Pietrantuono G, Guella A, Levato L, Mulas O, Saccona F, Rosti G, Musto P, Di Raimondo F, Pane F, Baccarani M, Saglio G, and Ciccone G

Abstract

An observational prospective study was conducted by the CML Italian network to analyze the role of baseline patient characteristics and first line treatments on overall survival and CML-related mortality in 1206 newly diagnosed CML patients, 608 treated with imatinib (IMA) and 598 with 2 nd generation tyrosine kinase inhibitors (2GTKI). IMA-treated patients were much older (median age 69 years, IQR 58-77) than the 2GTKI group (52, IQR 41-63) and had more comorbidities. Estimated 4-year overall survival of the entire cohort was 89% (95%CI 85.9-91.4). Overall, 73 patients (6.1%) died: 17 (2.8%) in the 2GTKI vs 56 (9.2%) in the IMA cohort (adjusted HR=0.50; 95% CI=0.26-0.94), but no differences were detected for CML-related mortality (10 (1.7%) vs 11 (1.8%) in the 2GTKIs vs IMA cohort (sHR=1.61; 0.52-4.96). The ELTS score was associated to CML mortality (high risk vs low, HR=9.67; 95%CI 2.94-31.74; p<0.001), while age (per year, HR=1.03; 95%CI 1.00-1.06; p=0.064), CCI (4-5 vs 2, HR=5.22; 95%CI 2.56-10.65; p<0.001), ELTS score (high risk vs low, HR=3.11; 95%CI 1.52-6.35, p=0.002) and 2GTKI vs IMA (HR=0.26; 95%CI 0.10-0.65, p=0.004) were associated to an increased risk of non-related CML mortality. The ELTS score showed a better discriminant ability than the Sokal score in all comparisons., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Specchia, Pregno, Breccia, Castagnetti, Monagheddu, Bonifacio, Tiribelli, Stagno, Caocci, Martino, Luciano, Pizzuti, Gozzini, Scortechini, Albano, Bergamaschi, Capodanno, Patriarca, Fava, Rege-Cambrin, Sorà, Galimberti, Bocchia, Binotto, Reddiconto, DiTonno, Maggi, Sanpaolo, De Candia, Giai, Abruzzese, Miggiano, La Barba, Pietrantuono, Guella, Levato, Mulas, Saccona, Rosti, Musto, Di Raimondo, Pane, Baccarani, Saglio and Ciccone.)

Published
2021
Full Text
View/download PDF

45. Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes.

Author

Musto P, Falcone A, Sanpaolo G, Bisceglia M, Matera R, and Carella AM

Subjects
Aged, Aged, 80 and over, Anemia, Refractory, with Excess of Blasts blood, Anemia, Refractory, with Excess of Blasts therapy, Combined Modality Therapy, Drug Evaluation, Erythropoietin blood, Female, Fetal Hemoglobin analysis, Humans, Male, Middle Aged, Thalidomide adverse effects, Treatment Outcome, Anemia, Refractory, with Excess of Blasts drug therapy, Blood Transfusion, Thalidomide therapeutic use
Published
2002

46. Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report.

Author

Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carotenuto M, and Carella AM

Subjects
Aged, Aged, 80 and over, Anti-Bacterial Agents standards, Anti-Bacterial Agents therapeutic use, Anti-Bacterial Agents toxicity, Clarithromycin standards, Clarithromycin toxicity, Drug Evaluation, Female, Humans, Male, Middle Aged, Protein Synthesis Inhibitors standards, Protein Synthesis Inhibitors therapeutic use, Protein Synthesis Inhibitors toxicity, Treatment Outcome, Clarithromycin therapeutic use, Multiple Myeloma drug therapy
Published
2002

47. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.

Author

Grossi A, Musto P, Santini V, Balestri F, Fabbri A, Falcone A, and Sanpaolo G

Subjects
Aged, Aged, 80 and over, Drug Evaluation, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Recombinant Proteins, Treatment Outcome, Amifostine administration & dosage, Erythropoietin administration & dosage, Myelodysplastic Syndromes drug therapy
Abstract

Twelve patients with myelodysplasia were treated with amifostine plus recombinant human erythropoietin (rHuEpo) for 6 weeks. A complete erythroid response was obtained in 2/12(16.6%) and a partial response in 4/12 (33.3%). Two of 8 patients with a platelet count < 100 x 10(9)/L had a complete response, as did 3/9 with a neutrophil count < 1.5 x 10(9)/L. Compared to rHuEpo or amifostine used as single agents, their combination did not offer substantial advantages.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results